Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion
The French pharmaceutical group said Tuesday that the deal for privately-held Vicebio includes an upfront payment of $1.15 billion and potential payments of up to $450 million subject to achieving certain development and regulatory milestones.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
AstraZeneca Announces $50B US Investment Amid Pharma Tariff Threat
AstraZeneca (AZN, Financials) said Monday it will invest $50 billion in the United States by 2030 to expand manufacturing and research, positioning itself ahead of potential import tariffs under President Donald Trump's administration. The British-Swedish pharmaceutical firm said the plan includes building a new manufacturing facility in Virginiaits largest single capital outlay in 26 yearsand expanding operations across Maryland, Massachusetts, California, Indiana, and Texas. The spending will also support AstraZeneca's U.S. clinical trial supply network and development of weight-loss and cardiovascular drugs. CEO Pascal Soriot unveiled the plan in Washington, calling for other countries to pay more for drugs to balance global research funding. The United States cannot build or carry the cost of R&D for the entire world, he said. The company aims to reach $80 billion in annual revenue by 2030, with half of that coming from the U.S., which already accounted for over 40% of sales in 2024. The move follows similar announcements from Roche (ROG, Financials), Eli Lilly (LLY, Financials), Johnson & Johnson (JNJ, Financials), Novartis (NOVN, Financials), and Sanofi (SASY, Financials). Commerce Secretary Howard Lutnick said the plan aligns with Trump's push to reduce reliance on foreign-made drugs. Our nation's new tariff policies are focused on ending this structural weakness, he said in a statement released by the company. AstraZeneca said the investment could add tens of thousands of new jobs. The company employs around 18,000 people in the U.S. and 90,000 globally. The pledge builds on $3.5 billion in investments announced last year and comes as the company evaluates a possible shift in its stock listing from London to New York. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
Blockstream Expands in Europe With Acquisition of Swiss Crypto Firm Elysium Labs
Adam Back's Bitcoin development firm, Blockstream, has acquired Swiss blockchain startup Elysium Labs. The acquisition will see the creation of a European incubator entity, Blockstream CH SAGL, according to an emailed announcement shared with CoinDesk on Monday. The deal terms weren't disclosed by the firms. Blockstream is building momentum around its European ventures, following the inception of its Lugano Research Center, which is focused on product development of Bitcoin layer-2 networks Lightning and Liquid. The firm has not disclosed financial details of the acquisition. Blockstream CH SAGL will serve as a hub for Blockstream's European operations alongside its Turin, Italy-based research and development team and the Lugano Research Center, according to Monday's announcement. An early proponent of the cypherpunk movement, Blockstream CEO and co-founder Adam Back is a notable figure in Bitcoin lore. Back developed Hashcash in 1997 to combat email spam, which was a direct influence on Satoshi Nakamoto in creating Bitcoin's proof-of-work mechanism, and was cited as such in the original whitepaper. 'Bringing Elysium Lab into Blockstream strengthens our Swiss presence and amplifies our commitment to nurturing innovation across Europe,' Back said in Monday's announcement. Read More: Adam Back's Bitcoin Treasury Firm to Go Public with 30K BTC and $1.5B in Buying Power
Yahoo
an hour ago
- Yahoo
Stellantis Posts $2.7B First-Half Loss as Tariffs Hit Jeep Maker
Stellantis (STLA, Financials) reported a 2.3 billion ($2.7 billion) net loss for the first half of 2025, reversing a 5.6 billion profit from the same period a year ago, as tariffs, restructuring costs and weak shipments hit the automaker's bottom line. In preliminary results released Monday, the Jeep and Chrysler parent said it incurred 300 million ($349 million) in costs from early impacts of new U.S. tariffs. Revenue dropped 13% year over year to 74.3 billion from 85 billion. The company had suspended its full-year outlook in April citing tariff-related uncertainty. North American vehicle shipments in the second quarter fell 25% to 109,000 units, though U.S. retail sales were described as relatively flat, supported by a 13% gain from Jeep and Ram combined. Overall global sales declined 10% from a year earlier. This is the first earnings report under new CEO Antonio Filosa, who took over following the sudden exit of Carlos Tavares last December. Final results are due July 29. UBS analysts said Monday that Stellantis' free cash flow is likely to remain negative in 2025, as the second half is unlikely to offset the first-half cash burn. Shares were little changed in premarket trading and are down nearly 30% year to date. This article first appeared on GuruFocus.
